Qdenga® - A promising dengue fever vaccine; can it be recommended to non-immune travelers?

Qdenga® has been approved by the European Medicines Agency (EMA) for individuals > 4 years of age and for use according to national recommendations. The vaccine shows high efficacy against virologically confirmed dengue and severe dengue in clinical studies on 4–16-year old's living in endem...

Full description

Bibliographic Details
Published in:Travel Medicine and Infectious Disease
Main Authors: Martin Angelin, Jan Sjölin, Fredrik Kahn, Anna Ljunghill Hedberg, Anja Rosdahl, Paul Skorup, Simon Werner, Susanne Woxenius, Helena H. Askling
Format: Article in Journal/Newspaper
Language:English
Published: Elsevier 2023
Subjects:
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
Arctic
Online Access:https://doi.org/10.1016/j.tmaid.2023.102598
https://doaj.org/article/f875f822f19a4008ac132eaff93b73b4
Description
Summary:Qdenga® has been approved by the European Medicines Agency (EMA) for individuals > 4 years of age and for use according to national recommendations. The vaccine shows high efficacy against virologically confirmed dengue and severe dengue in clinical studies on 4–16-year old's living in endemic areas. For individuals 16–60 years old only serological data exists and there is no data for individuals > 60 years. Its use as a travel vaccine is still unclear. We present the studies behind the approval and the recommendations for travelers as issued by the Swedish Society for Infectious Diseases Physicians.

Similar Items